Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Port Jervis Laboratories, Inc.
EIR
•Port Jervis Laboratories, Inc.•February 28, 2011

Port Jervis Laboratories, Inc. – FDA EIR, Feb 28, 2011

Record Details

An FDA inspection of Kolmar Laboratories Inc., a contract manufacturer of over-the-counter drug and cosmetic products located in Port Jervis, NY, took place from February 18 to 28, 2011. This focused inspection evaluated the company's quality, equipment and facilities, and laboratory control systems, adhering to drug manufacturing inspection guidelines and Good Manufacturing Practices regulations. The inspection identified several issues, documented in an FDA-483 form. Key violations included the company's failure to thoroughly investigate batches that did not meet specifications, particularly concerning active ingredients such as Oxybenone and Octinoxate, without implementing appropriate corrective and preventive actions. Additionally, the firm was cited for not consistently following its own warehousing procedures for drug products, which resulted in raw materials lacking proper status labels and certain products being stored at incorrect temperatures. Laboratory records were also found to be incomplete, specifically missing detailed calculations for release testing. Verbal observations from the inspection highlighted concerns with unrepresentative in-process sampling, incomplete batch records, and an uncalibrated laboratory fume hood. Kolmar Laboratories Inc. acknowledged these observations and committed to addressing the identified deficiencies. The company pledged to submit a formal written response to the district office within 15 business days, outlining their corrective actions. During the inspection, some immediate voluntary corrections were initiated, including the calibration of the fume hood and the implementation of new temperature and humidity monitoring forms.

Company
Port Jervis Laboratories, Inc.
Inspection date
February 28, 2011
Product type
drugs
Office
New York District Office
People
  • Jeffrey Swaine (company_representative)
  • Sony Mathews (Consumer Safety Officer Drug Specialist)
  • Robert J. Edmonds (recipient)
  • Thomas J. Calcagno (recipient)
  • William Jablesnik (company_representative)
View Company Profile

ID · 86b0de8e-6435-4531-80fb-aed3a3018348

Violation Codes3
21 CFR 211.19221 CFR 211.194(a)(5)21 CFR 211.142

Full citation text and observation details available on the Dashboard.

Other documents for Port Jervis Laboratories, Inc.
  • 483 - 2022-11-04November 4, 2022
  • EIR - 2022-11-04November 4, 2022
  • EIR - 2018-01-25January 25, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Port Jervis Laboratories, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.